Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Restructuring Costs (2021 - 2023)

Historic Restructuring Costs for Theravance Biopharma (TBPH) over the last 3 years, with Q2 2023 value amounting to $1.2 million.

  • Theravance Biopharma's Restructuring Costs fell 6109.82% to $1.2 million in Q2 2023 from the same period last year, while for Dec 2023 it was $2.7 million, marking a year-over-year decrease of 9394.87%. This contributed to the annual value of $2.7 million for FY2023, which is 7863.37% down from last year.
  • Per Theravance Biopharma's latest filing, its Restructuring Costs stood at $1.2 million for Q2 2023, which was down 6109.82% from $1.6 million recorded in Q1 2023.
  • In the past 5 years, Theravance Biopharma's Restructuring Costs ranged from a high of $33.0 million in Q3 2022 and a low of $1.2 million during Q2 2023
  • In the last 3 years, Theravance Biopharma's Restructuring Costs had a median value of $3.0 million in 2022 and averaged $9.7 million.
  • Its Restructuring Costs has fluctuated over the past 5 years, first skyrocketed by 176335.4% in 2022, then plummeted by 8311.88% in 2023.
  • Over the past 3 years, Theravance Biopharma's Restructuring Costs (Quarter) stood at $18.4 million in 2021, then soared by 79.63% to $33.0 million in 2022, then plummeted by 96.46% to $1.2 million in 2023.
  • Its Restructuring Costs stands at $1.2 million for Q2 2023, versus $1.6 million for Q1 2023 and $33.0 million for Q3 2022.